- Open Access
Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study
World Journal of Surgical Oncology volume 19, Article number: 95 (2021)
The feasibility of association liver partition and portal vein ligation for staged hepatectomy (ALPPS) for solitary huge hepatocellular carcinoma (HCC, maximal diameter ≥ 10 cm) remains uncertain. This study aims to evaluate the safety and the efficacy of ALPPS for patients with solitary huge HCC.
Twenty patients with solitary huge HCC who received ALPPS during January 2017 and December 2019 were retrospectively analyzed. The oncological characteristics of contemporaneous patients who underwent one-stage resection and transcatheter arterial chemoembolization (TACE) were compared using propensity score matching (PSM).
All patients underwent complete two-staged ALPPS. The median future liver remnant from the ALPPS-I stage to the ALPPS-II stage increased by 64.5% (range = 22.3–221.9%) with a median interval of 18 days (range = 10–54 days). The 90-day mortality rate after the ALPPS-II stage was 5%. The 1- and 3-year overall survival (OS) rates were 70.0% and 57.4%, respectively, whereas the 1- and 3-year progression-free survival (PFS) rates were 60.0% and 43.0%, respectively. In the one-to-one PSM analysis, the long-term survival of patients who received ALPPS was significantly better than those who received TACE (OS, P = 0.007; PFS, P = 0.011) but comparable with those who underwent one-stage resection (OS, P = 0.463; PFS, P = 0.786).
The surgical outcomes of ALPPS were superior to those of TACE and similar to those of one-stage resection. ALPPS is a safe and effective treatment strategy for patients with unresectable solitary huge HCC.
Hepatocellular carcinoma (HCC) is a lethal malignancy with a poor prognosis and limited therapeutic options, accounting for approximately 841,000 new cases and 782,000 deaths worldwide each year . Current treatment strategies for HCC mainly include surgical resection, transplantation, radiofrequency ablation, transarterial chemoembolization, chemotherapy, and radiotherapy . Surgical resection allows patients to acquire better long-term survival than other treatments in most cases [3, 4] and remains the major treatment for HCC [2, 5]. Considering the radical surgical treatment for HCC, the extensive radical resection for tumor removal may lead to insufficient future liver remnant (FLR) and subsequently cause posthepatectomy liver failure and even death. A huge HCC (maximal diameter ≥ 10 cm) is a common and direct factor for the deficiency of FLR in clinical practice. Patients with huge HCC frequently lose the chance of radical treatment, thereby limiting the feasibility of the hepatic resection. Previous studies indicate that the 5-year overall survival (OS) in patients with huge HCC who have undergone nonsurgical treatment is less than 20%, which is significantly lower than those who have undergone surgical resection (about 25–40%) [6,7,8].
The association liver partition and portal vein ligation for staged hepatectomy (ALPPS), an innovative procedure of hepatectomy, can effectively induce the rapid hypertrophy of FLR within a short time [9,10,11]. This strategy of accelerated regeneration enables extensive hepatic resection well beyond the safe resection of 70% of liver volume , creating an opportunity for patients with unresectable HCC. Although ALPPS is controversial in the initial application due to severe complications and high early mortality, the situation has occurred in the evidently improved prognosis of ALPPS over time. A continuous decrease in the postoperative morbidity and the early mortality makes ALPPS reach standard outcomes accepted for major liver surgery . ALPPS increases the resection rates of HCC. However, patients with solitary huge HCC who have undergone ALPPS may have increased potential risks because of the bulky tumor volume and the insufficient FLR. Currently, the efficacy and the safety of ALPPS for the treatment of solitary huge HCC are rarely reported and remain uncertain.
This study aims to explore the feasibility of ALPPS in the treatment of patients with solitary huge HCC. The propensity score matching (PSM) analysis is used, and the oncologic outcomes of one-stage resection for resectable solitary huge HCC are compared with those of the transcatheter arterial chemoembolization (TACE) for the unresectable tumor.
Study design and ethics
In this study, consecutive patients diagnosed with solitary huge HCC (maximal diameter ≥ 10 cm) and underwent ALPPS at the First Affiliated Hospital of Guangxi Medical University between January 2017 and December 2019 were enrolled. The oncological data of these patients were retrospectively analyzed and compared with those of patients who underwent one-stage resection and TACE during the same period by using the PSM analysis. This study was approved by the local Ethics Committee (approval number: 2020KY-E-110) and conducted in accordance with the 1990 Declaration of Helsinki and the following amendments. Written informed consents were obtained from each patient before using their clinical data for research.
Transient elastography (TE) and imageological examination, such as computed tomographic (CT), magnetic resonance imaging (MRI), or ultrasonography, were combined to evaluate the preoperative degree of liver fibrosis or cirrhosis [14,15,16]. The FLR value and the standard liver volume (SLV) of each patient were calculated at the same time. The insufficient FLR was defined as follows: (1) FLR/SLV < 50%, severe fibrosis or cirrhosis; (2) FLR/SLV < 40%, mild/moderate fibrosis; and (3) FLR/SLV < 30%, without liver fibrosis or cirrhosis. In this study, patients with solitary huge HCC and sufficient FLR underwent one-stage resection, and patients with insufficient FLR underwent ALPPS or TACE. In addition, the choice of treatment strategy should be based on the patient’s intentions and preoperative liver function.
Patients receiving TACE were diagnosed with HCC by using two of three imageological examinations (i.e., CT, MRI, and ultrasonography) combined with the serum alpha-fetoprotein (AFP) level > 400 ng/mL or by needle biopsy to determine the suspected diagnosis. Finally, the maximum tumor diameter was measured using imageological examinations to diagnose the solitary huge HCC. All image analysis was interpreted by two or more professional reviewers with an inter-observer agreement.
Patients who had received any initial treatment for HCC, such as chemotherapy, radiotherapy, or sorafenib, within 6 months were excluded from this study. Patients with incomplete clinical records and lost to follow-up were excluded.
The FLR volume was measured using the digital software of intelligent/interactive qualitative and quantitative analyses (IQQA-Liver; EDDA Technology Inc., Princeton, NJ). The SLV was calculated on the basis of the estimation formula of standard liver volume for Chinese adults . Thus, the preoperative FLR/SLV was measured to determine whether FLR was insufficient. The increases in the volume of FLR after the ALPPS-I stage were confirmed to assess whether to continue to the ALPPS-II stage. The following conditions were considered to proceed with the operation of the ALPPS-II stage : (1) FLR/SLV ≥ 50% with severe fibrosis or cirrhosis, (2) FLR/SLV ≥ 40% with mild/moderate fibrosis, and (3) FLR/SLV ≥ 30% without liver fibrosis or cirrhosis.
In the operation of the ALPPS-I stage, the abdomen was first opened through the reverse “L” incision and explored to confirm any distant metastasis in the peritoneum. The intraoperative ultrasonography was used to re-evaluate the location, size, number of tumor, and the position of adjacent blood vessels especially the anatomical positional relationship of the right, middle, and left hepatic veins. The liver resection line along or near the right side of the falciform ligament was subsequently marked, and the gallbladder was removed. The right portal vein was separated and ligated. Finally, the liver parenchyma was transected, and occlusion of the middle and left hepatic veins was performed to reduce intraoperative bleeding. Patients were confirmed without bile leakage before closing the abdomen.
The operation of the ALPPS-II stage was performed when the volumetric measurement demonstrated sufficient FLR volume and the patient’s overall condition was acceptable. In the operation of the ALPPS-II stage, the abdomen was opened again along the original surgical incision. The right hepatic artery, right portal vein, right hepatic duct, short hepatic vein, and perihepatic ligaments were transected to remove the tumor-bearing liver. Tumor specimens were used for pathological diagnosis.
Patients were termly followed once every month from discharge to the first 3 months and every 3–6 months thereafter in our outpatient department of liver surgery. The main contents of the follow-up include imageological examinations, chest radiography, liver function, and serum AFP level.
The OS and the progression-free survival (PFS) rates of each patient after the PSM analysis were calculated until August 1, 2020. The survival time was defined as the period between therapeutic operations and the date of death or last contact. The terminal event of PFS included distant metastasis, recurrence, and death after ALPPS and one-stage resection, extrahepatic or intrahepatic metastasis, and death after TACE.
The PSM analysis was performed to minimize the effect of patient selection bias and baseline differences between patients who received ALPPS and one-stage resection or TACE. The 1:1 matching with a 0.1 caliper width was constructed using the logistic regression model on the basis of the age, gender, body mass index, model for end-stage liver disease (MELD) score, serum AFP level, Child-Pugh grade, tumor size, vascular invasion, and extrahepatic metastasis. The variable balance between the matched groups was assessed using the paired t test, the chi-square test, or the 2-tailed Fisher exact test. The OS and PFS of ALPPS were compared with one-stage resection and TACE after PSM analysis.
Quantitative variables were expressed as median with ranges, and categorical variables were presented as the number of cases with percentage. The 1:1 matching between ALPPS and one-stage resection/TACE cohorts was performed using the PSM functional module in the SPSS . The Kaplan-Meier method was used to calculate the 1- and 3-year OS and PFS rates. The log-rank test was used to assess the differences in survival outcomes. The Cox regression analysis was carried out to identify the potential risk factors for poor outcomes. All statistical analyses were performed using the SPSS software (version 20; IBM, Chicago, IL). P < 0.05 was considered statistically significant.
Twenty patients diagnosed with solitary huge HCC had undergone ALPPS at our hospital during January 2017 and December 2019. These patients had a single tumor in the liver with a median diameter of 14.5 cm (range = 10.0–21.0 cm). The median age was 47 years (range = 32–75 years). The median preoperative MELD score was 5 (range = 2–11), and the median rate of the indocyanine green retention at 15 min was 4.4% (range = 2.4–10.9%). In accordance with the Child-Pugh classification, 19 (95%) and 1 (5%) patients were classified as classes A and B, respectively, whereas in accordance with the Barcelona Clinic Liver Cancer staging, 7 (35%), 5 (25%), and 8 (40%) patients were classified as stages A, B, and C, respectively. The baseline characteristics at preoperation are shown in Table 1.
Intraoperative and postoperative data of ALPPS
All patients received the complete two-staged ALPPS operation. A total of 17 (85%) patients underwent the right hemihepatectomy ALPPS, 2 (10%) patients underwent the extended right hemihepatectomy ALPPS, and 1 (5%) patient underwent the right trisectionectomy ALPPS. The median interval between the ALPPS-I and the ALPPS-II stages was 18 days (range = 10–54 days).
No anesthesia accident occurred during the ALPPS operation. Eighteen patients met the criteria for negative margins (R0 resection), and the two remaining patients underwent the R1 resection. Moreover, one patient had bile leakage after the operation of the ALPPS-II stage. The incidences of severe complications (classification ≥ III) were 20% and 25% after the ALPPS-I and the ALPPS-II stages, respectively. The postoperative pathological diagnosis verified that the pathological types of these 20 patients were all HCC. The intraoperative and the postoperative data are summarized in Table 2.
Volumetric assessment during ALPPS procedure
The CT diagram of the liver and the reconstructed 3D model via IQQA during perioperation of ALPPS are illustrated in Fig. 1. The liver volume-related data, including SLV, FLR, FLR/SLV ratio, and the increases in FLR, are presented in Table 3. The median increase in the FLR volume between the ALPPS-I and the ALPPS-II stages was 64.5% (range = 22.3–221.9%), and the FLR volume at preoperation of the ALPPS-II stage was significantly higher than that of the ALPPS-I stage (P < 0.001).
The absolute and the relative kinetic growth rates (KGR) of FLR were 21.7 cm3/day (range = 11.5–42.3 cm3/day) and 2.1%/day (range = 0.8–10.2%/day), respectively. The median KGR of patients with Ishak fibrosis scores of 1&2, 3&4, and 5&6 were 37.2 (range 20.1–42.3 cm3/day), 23.2 (range 14.7–37.0 cm3/day), and 14.6 (range 13.1–18.0 cm3/day) cm3/day, respectively (Fig. 2). Patients with Ishak fibrosis scores of 1&2 or 3&4 had significantly higher KGR than those with Ishak fibrosis scores of 5&6 (scores 1&2 vs. 5&6: P = 0.014; scores 3&4 vs. 5&6: P = 0.009).
The median follow-up time of all patients with solitary huge HCC who underwent ALPPS was 21.3 months (range = 12.1–41.6 months). One patient (5%) died within 90 days after surgery of the ALPPS-II stage. The 1- and 3-year OS rates of the ALPPS group were 70.0% and 57.4%, respectively. The 1- and 3-year PFS rates were 60.0% and 43.0%, respectively. The tumor recurrence, pulmonary metastasis, and death were observed in 1, 2, and 8 patients, respectively, during follow-up. The univariable Cox regression analysis identified the MELD score and the postoperative complications of the ALPPS-II stage ≥ III as risk factors for poor OS. Further multivariate analysis indicated that the two factors significantly affected the outcome after the ALPPS procedure (Table S1).
Survival analysis was performed to total patients enrolled in this study including 20 cases that underwent treatment for ALPPS, 110 for one-stage resection, and 66 for TACE. The results showed that the 1- and 3-year OS rates of all patients with one-stage resection were 76.7% and 45.2%, respectively (Fig. 3a, P = 0.770), and the 1- and 3-year PFS rates were 72.0% and 41.3%, respectively (Fig. 3b, P = 0.483), no significant difference compared with ALPPS in survival outcomes. In addition, the 1- and 3-year OS rates of all patients with TACE were 58.9% and 24.9%, respectively (Fig. 3a, P = 0.045), and the 1- and 3-year PFS rates were 33.1% and 17.5%, respectively (Fig. 3b, P = 0.034); patients with ALPPS had significantly better outcomes than those with TACE.
To reduce the influence of confounding factors for survival analysis, PSM analysis was used to further compare the outcomes of different therapy strategies for patients with solitary huge HCC. During the same research period, 20 of 110 patients with solitary huge HCC who underwent one-stage resection were selected to match those who received ALPPS, which made the oncological characteristics between the two groups as close as possible by the PSM analysis (Table S2). The 1- and 3-year OS rates of the matched one-stage resection group were 63.6% and 42.4%, respectively (Fig. 4a, P = 0.463). The 1- and 3-year PFS rates were 59.2% and 31.6%, respectively (Fig. 4b, P = 0.786). The survival analysis revealed no significant difference in the OS and PFS of ALPPS and one-stage resection groups.
Of the 66 patients with solitary huge HCC who underwent TACE, 20 were matched with the ALPPS group by using the PSM analysis (Table S3). TACE group had 1- and 3-year OS rates of 40.0% and 15.6%, respectively (Fig. 5a, P = 0.007). ALPPS group had 1- and the 3-year PFS rates of 35.0% and 6.0%, respectively (Fig. 5b, P = 0.011). Survival curves showed that the ALPPS group had significantly better outcomes than the TACE group.
Since its first public report in 2012 , ALPPS has been gradually promoted and applied in clinical practice. Increasing evidence suggests that ALPPS can remarkably improve the resectability of liver cancer and give patients with unresectable huge HCC an opportunity of curative resection [11, 20,21,22]. The present study has focused on patients with solitary huge HCC and compared the efficacy and the safety of ALPPS, one-stage resection, and TACE. Our results indicate that the OS of the ALPPS group is similar to that of the propensity score-matched one-stage resection group and significantly better than that of the matched TACE group.
One-stage resection and TACE are common clinical strategies for HCC treatment. Previous studies have compared the efficacy of one-stage resection and TACE in the treatment of solitary huge HCC, and the results show that one-stage resection can achieve improved outcomes [23, 24]. However, the feasibility of ALPPS, as a novel procedure of liver surgery, in solitary huge HCC has not been independently reported. The present study complements previous reports by adding ALPPS treatment to the analysis. Notably, our pivotal results show that ALPPS is safe and effective in unresectable cases with solitary huge HCC, comparable with one-stage resection, and superior to TACE on the curative effect.
The inadequate FLR is a direct challenge to the surgical treatment of solitary huge HCC especially one-stage resection, which is inclined to cause serious complications (such as liver failure and small-for-size syndrome after hepatectomy). By contrast, ALPPS can induce accelerated hypertrophy to acquire a sufficient volume of FLR through staged hepatectomy. Therefore, the appearance of ALPPS broadens the extent of indications for solitary huge HCC. In some centers, the conventional two-staged resection with portal vein ligation (PVL) or embolization (PVE) is also performed to induce the FLR hypertrophy in patients with unresectable HCC, but a relatively long waiting time is required to achieve adequate FLR volume compared with ALPPS [25, 26]. Approximately 20–38% of patients are ineligible for the curative resection after two-staged resection with PVL or PVE due to local tumor progression or extrahepatic metastasis [20, 27,28,29]. A recent study reports that ALPPS can improve the survival in patients with colorectal liver metastases and FLR < 30% compared with the conventional two-staged resection .
ALPPS is labeled as a high-risk operation due to its initially reported high morbidity and mortality . However, a learning curve in ALPPS is observed, and things have gone into gradually reverse as improvement of patient selection, interstage management, and ALPPS technique [32, 33]. A study of the International ALPPS Registry shows that the 90-day mortality decreases from 17 to 4% in 2015 among 437 patients from 16 centers . In this study, the 90-day mortality rate in 20 patients after ALPPS for solitary huge HCC is 5%. Our results are similar to the data reported in this longitudinal study. Noticeably, the decrease of ALPPS-associated risk is largely due to strict patient selection. From the data of the international registry, patients more than 60 years old have more severe postoperative complications (Clavien-Dindo IIIb or above) and higher mortality. Thus, elderly patients are poor candidates for ALPPS . In addition, ALPPS are commonly used for patients with lower FLR volume; however, there is no consensus on the ideal index of FLR for ALPPS. A recent prospective trial suggested that ALPPS was performed on patients with FLR/SLV less than 30% when ALPPS was compared with conventional hepatectomy . In clinical practice, potential liver diseases such as Child-Pugh grade, MELD score, fibrosis/cirrhosis, portal hypertension, and cholestasis are also important factors in surgical decision-making. Liver fibrosis/cirrhosis is a special concern for ALPPS in the treatment of HCC. A previous study demonstrated that the increase of FLR volume was negatively associated with the severity of liver fibrosis/cirrhosis . Therefore, ALPPS should be carefully applied to patients with liver cirrhosis. For the perioperative management of ALPPS, the key is in the ALPPS-I stage. To assess the patient’s condition, except for monitoring conventional biochemical indicators, the pathological staging of liver cirrhosis was acquired based on the Ishak score , the classification of postoperative liver failure was evaluated according to the International Liver Surgery Research Group (ISGLS) , and the severity of postoperative complication was identified by the Clavien-Dindo classification . CT imaging was performed on the 3rd, 7th, and 14th day after ALPPS-I operation, and the IQQA digital analysis software was used to calculate the FLR volume, which can assist in a more exact assessment of FLR increase to implement ALPPS-II operation as soon as possible. In recent years, a variety of modified ALPPS procedures was reported to improve the safety and the feasibility of ALPPS [38,39,40,41,42], greatly promoting the development and maturity of ALPPS technology. Moreover, some emerging liver image analysis systems also assist the improvement of ALPPS. For instance, preoperative FLR prediction using IQQA can be more effective and exact for patient selection . Using the Liver Imaging Reporting and Data System (LI-RADS) to diagnose and classify HCC can achieve better screening and management [44, 45].
In addition, our results suggest that ALPPS can accelerate the FLR hypertrophy to reach sufficient volume for hepatic resection. However, severe liver fibrosis or cirrhosis may exert an adverse influence on the FLR hypertrophy between the ALPPS-I and the ALPPS-II stages. Patients with Ishak fibrosis scores of 5&6 have the lowest KGR compared with those with Ishak fibrosis scores of 1–4. Wang et al.  published their results with ALPPS that the median KGR of HCC patients with the absence of fibrosis/cirrhosis, mild fibrosis, moderate fibrosis, severe fibrosis, cirrhosis were 50.1, 19.0, 16.8, 19.8, and 9.6 cm3/day, respectively. Chan et al.  reported that the median KGR of patients with chronic hepatitis and cirrhosis were 24.6 and 20.7 cm3/day, respectively. Our results are approximate to these previous reports. Therefore, ALPPS should be prudently used in patients with cirrhosis or severe fibrosis.
The present study has identified the MELD score and the postoperative complications of ALPPS-II stage ≥ III as independent predictors of poor outcomes. In previous studies, a high MELD score and the Clavien-Dindo classification are demonstrated to be the risk factors for the poor prognosis of HCC [46,47,48]. Our data show that TACE is less effective in the treatment of solitary huge HCC. In most cases, TACE alone is not the optimal treatment for solitary huge HCC [7, 23, 24].
In this study, we screened the special type of HCC—solitary huge HCC—and demonstrated and compared the efficacy of ALPPS, one-stage resection, and TACE. However, several limitations need to be mentioned. First, the number of included cases in this single-center study is few, which is prone to potential bias. Second, the analysis of the modified ALPPS procedure and the two-staged resection with PVL or PVE is lacking because of the absence of these cases. Finally, the PSM analysis does not eliminate the selection bias completely. Thus, a rigorous multicenter randomized controlled trial should be designed to further verify the results.
In conclusion, this work suggests that ALPPS is feasible for patients with solitary huge HCC. ALPPS enables the possibility of the curative resection of solitary huge HCC in patients who are perceived to have unresectable tumors in indications of conventional hepatectomy. The long-term OS after ALPPS is significantly superior to that after TACE and comparable with that after one-stage hepatic resection. For patients with unresectable solitary huge HCC, ALPPS is an alternative treatment that cannot be ignored.
Availability of data and materials
The datasets analyzed during the current study are available from the corresponding authors on reasonable request.
Association liver partition and portal vein ligation for staged hepatectomy
Transcatheter arterial chemoembolization
Propensity score matching
Future liver remnant
Magnetic resonance imaging
Standard liver volume
Intelligent/interactive qualitative and quantitative analyses
Model for end-stage liver disease
Kinetic growth rate
Portal vein ligation
Portal vein embolization
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-A Cancer Journal For Clinicians. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. https://doi.org/10.1002/hep.29086.
Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40. https://doi.org/10.1097/SLA.0000000000000236.
Xiao H, Zhang B, Mei B, Zuo C, Wei G, Wang R, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation. Medicine. 2015;94(7):e495. https://doi.org/10.1097/MD.0000000000000495.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70. https://doi.org/10.1007/s12072-017-9799-9.
Mok K, Wang B, Lo G, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surgeons. 2003;197(5):730–8. https://doi.org/10.1016/j.jamcollsurg.2003.07.013.
Min YW, Lee JH, Gwak G-Y, Paik YH, Lee JH, Rhee PL, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroen Hepatol. 2014;29(5):1043–8. https://doi.org/10.1111/jgh.12504.
Fang Q, Xie QS, Chen JM, Shan SL, Xie K, Geng XP, et al. Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: a single-center experience in China. Hepatobiliary Pancreat Dis Int. 2019;18(6):532–7. https://doi.org/10.1016/j.hbpd.2019.09.001.
Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–14. https://doi.org/10.1097/SLA.0b013e31824856f5.
Vennarecci G, Laurenzi A, Levi Sandri GB, Busi Rizzi E, Cristofaro M, Montalbano M, et al. The ALPPS procedure for hepatocellular carcinoma. Eur J Surg Oncol. 2014;40(8):982–8. https://doi.org/10.1016/j.ejso.2014.04.002.
Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients. Ann Surg. 2018;271(3):534–41.
Lang H, de Santibanes E, Schlitt HJ, et al. 10th anniversary of ALPPS-lessons learned and quo vadis. Ann Surg. 2018;269(1):114–9.
Linecker M, Bjornsson B, Stavrou GA, et al. Risk adjustment in ALPPS is associated with a dramatic decrease in early mortality and morbidity. Ann Surg. 2017;266(5):779–86. https://doi.org/10.1097/SLA.0000000000002446.
Kemp W, Levy M, Weltman M, Lubel J, Australian Liver Association (ALA). Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroen Hepatol. 2015;30(3):453–62. https://doi.org/10.1111/jgh.12865.
Cazzagon N, Lemoinne S, El Mouhadi S, et al. The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis. Am J Gastroenterol. 2019;114(12):1878–85. https://doi.org/10.14309/ajg.0000000000000461.
Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2016;43(4):458–69. https://doi.org/10.1111/apt.13488.
Li F, Yan L, Li B, Zeng Y, Wen TF, Xu MQ, et al. Estimation formula of standard liver volume for Chinese adults. Sichuan da xue xue bao: Yi xue ban. 2009;40(2):302–6.
Oldhafer KJ, Stavrou GA, van Gulik TM, Core Group. ALPPS--where do we stand, where do we go?: eight recommendations from the first international expert meeting. Ann Surg. 2016;263(5):839–41. https://doi.org/10.1097/SLA.0000000000001633.
Propensity score matching in SPSS. January 30, 2012. https://arxiv.org/abs/1201.6385 Accessed 1 Jan 2017.
Sandstrom P, Rosok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian multicenter randomized controlled trial (LIGRO Trial). Ann Surg. 2018;267(5):833–40. https://doi.org/10.1097/SLA.0000000000002511.
Alvarez FA, Ardiles V, de Santibanes M, et al. Associating liver partition and portal vein ligation for staged hepatectomy offers high oncological feasibility with adequate patient safety: a prospective study at a single center. Ann Surg. 2015;261(4):723–32. https://doi.org/10.1097/SLA.0000000000001046.
Ratti F, Schadde E, Masetti M, Massani M, Zanello M, Serenari M, et al. Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy. Ann Surg Oncol. 2015;22(6):1933–42. https://doi.org/10.1245/s10434-014-4291-4.
Zhu SL, Zhong JH, Ke Y, Ma L, You XM, Li LQ. Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. World J Gastroentero. 2015;21(32):9630–7. https://doi.org/10.3748/wjg.v21.i32.9630.
Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, et al. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med. 2020;8(5):238. https://doi.org/10.21037/atm.2019.12.157.
Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy. Ann Surg. 2019. Volume published online ahead of print. https://doi.org/10.1097/SLA.0000000000003433.
Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017;43(1):32–41. https://doi.org/10.1016/j.ejso.2016.05.026.
Aoki T, Kubota K. Preoperative portal vein embolization for hepatocellular carcinoma: consensus and controversy. World J Hepatol. 2016;8(9):439–45. https://doi.org/10.4254/wjh.v8.i9.439.
Aussilhou B, Lesurtel M, Sauvanet A, Farges O, Dokmak S, Goasguen N, et al. Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. J Gastrointest Surg. 2008;12(2):297–303. https://doi.org/10.1007/s11605-007-0410-x.
Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G, Huang SY, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201–9. https://doi.org/10.1016/j.jamcollsurg.2012.10.018.
Hasselgren K, Rosok BI, Larsen PN, et al. ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO. Ann Surg. 2021;273(3):442–8. https://doi.org/10.1097/SLA.0000000000003701.
Eshmuminov D, Raptis DA, Linecker M, Wirsching A, Lesurtel M, Clavien PA. Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg. 2016;103(13):1768–82. https://doi.org/10.1002/bjs.10290.
Hernandez-Alejandro R, Ruffolo LI, Alikhanov R, et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure for colorectal liver metastasis. Int J Surg. 2020;82(Supplement):103–8. https://doi.org/10.1016/j.ijsu.2020.04.009.
Al Hasan I, Tun-Abraham ME, Wanis KN, et al. Optimizing associated liver partition and portal vein ligation for staged hepatectomy outcomes: surgical experience or appropriate patient selection? Can J Surg. 2017;60(6):408–15. https://doi.org/10.1503/cjs.005817.
Au KP, Chan ACY. Current status of associating liver partition with portal vein ligation for staged hepatectomy: comparison with two-stage hepatectomy and strategies for better outcomes. World J Gastroenterol. 2019;25(43):6373–85. https://doi.org/10.3748/wjg.v25.i43.6373.
Ishak K, Baptista A, Bianchi L, Callea F, de Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9. https://doi.org/10.1016/0168-8278(95)80226-6.
Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713–24. https://doi.org/10.1016/j.surg.2010.10.001.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.
Tanaka K, Kikuchi Y, Kawaguchi D, Murakami T, Hiroshima Y, Matsuo K. Modified ALPPS procedures avoiding division of portal pedicles. Ann Surg. 2017;265(2):e14–20. https://doi.org/10.1097/SLA.0000000000001967.
Robles R, Parrilla P, Lopez-Conesa A, et al. Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure. Br J Surg. 2014;101(9):1129–34. https://doi.org/10.1002/bjs.9547.
Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200. https://doi.org/10.1097/SLA.0000000000000234.
Gall TM, Sodergren MH, Frampton AE, et al. Radio-frequency-assisted liver partition with portal vein ligation (RALPP) for liver regeneration. Ann Surg. 2015;261(2):e45–6. https://doi.org/10.1097/SLA.0000000000000607.
Petrowsky H, Gyori G, de Oliveira M, et al. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann Surg. 2015;261(4):e90–2. https://doi.org/10.1097/SLA.0000000000001087.
Chen L, Luo H, Dong S, Chen XP. Safety assessment of hepatectomy for huge hepatocellular carcinoma by three dimensional reconstruction technique. Zhonghua wai ke za zhi. 2016;54(9):669–74. https://doi.org/10.3760/cma.j.issn.0529-5815.2016.09.005.
Abdel Razek AAK, El-Serougy LG, Saleh GA, et al. Liver Imaging Reporting and Data System Version 2018: what radiologists need to know. J Comput Assist Tomogr. 2020;44(2):168–77. https://doi.org/10.1097/RCT.0000000000000995.
Abdel Razek AAK, El-Serougy LG, Saleh GA, et al. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy. Diagn Interv Imaging. 2020;101(9):547–53. https://doi.org/10.1016/j.diii.2020.03.008.
Vitale A. Huo T-l, Cucchetti A, et al. Survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. Ann Surg Oncol. 2014;22(6):1901–7. https://doi.org/10.1245/s10434-014-4099-2.
Kishida N, Hibi T, Itano O, Okabayashi K, Shinoda M, Kitago M, et al. Validation of hepatectomy for elderly patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(9):3094–101. https://doi.org/10.1245/s10434-014-4350-x.
Pravisani R, Baccarani U, Isola M, Adani G, Lorenzin D, Terrosu G, et al. Impact of surgical complications on the risk of hepatocellular carcinoma recurrence after hepatic resection. Updates Surg. 2018;70(1):57–66. https://doi.org/10.1007/s13304-017-0486-0.
The authors would like to thank Kaiyi Lu, Junxin He, Jian Li, Guolin Wu, Wei Wang, Jue Wang, and Qiling Yi for their help in volumetric measurement of the liver and collection of follow-up data.
This work was supported by the National Natural Science Foundation of China (grant no. 81560387, 81902983), the Guangxi Natural Science Foundation of China (grant no. 2018JJB140382), the “Medical Excellence Award” funded by the creative research development grant from the first affiliated hospital of Guangxi Medical University (grant no. 180327), the Guangxi Medical and Health Technology Development and Application Project (grant no. S2019097, S2018100), and the Emergency and Medical Rescue Talent Small Highland in Guangxi Zhuang Autonomous Region • Open Topics of Key Laboratory for Emergency Medicine in Guangxi Universities (grant no. GXJZ201501).
Ethics approval and consent to participate
This study was approved by the Ethics Committee of First Affiliated Hospital of Guangxi Medical University (approval number: 2020KY-E-110).
Consent for publication
The authors declare that they have no competing interests.
. Univariable and Multivariable Cox regression analysis of risk factors for survival outcomes after ALPPS procedure.
. Comparisons of baseline characteristics of patients with solitary huge HCC underwent ALPPS or one-stage resection before and after PSM.
. Comparisons of baseline characteristics of patients with solitary huge HCC underwent ALPPS or TACE before and after PSM.
About this article
Cite this article
Deng, Z., Jin, Z., Qin, Y. et al. Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study. World J Surg Onc 19, 95 (2021). https://doi.org/10.1186/s12957-021-02199-1
- Solitary huge hepatocellular carcinoma
- Future liver remnant